Dual-target GD2/B7-H3 CAR-NK cells

· Beijing Biotech

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Dual-target GD2/B7-H3 CAR-NK cells, covering 2026-03-30 to 2026-03-30. Get the full timeline:

Most recent: Clinical Trial Update: Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma [Phase 1, Phase 2]